Aegirbio AB has today signed a research & development agreement with MediaPharma Srl, an Italian biotech company focusing on novel drugs for the cure of cancer, and through this agreement Aegirbio intends to develop these drugs together with MediaPharma, in oncology and other areas.

The unique characteristic of the cooperation is that Aegirbio’s Veritope technology is combined with MediaPharma’s portfolio already in the development phase. Therapeutic Drug Monitoring, where diagnostics and drugs are developed in tandem will improve the precision of the treatment even further. In addition, MediaPharma will be able to move through the clinical phases of drug development faster and more reliably.

This represents a major stride, where Aegirbio opens up a novel business area centred on “Companion Diagnostics”; we are convinced that pharmaceutical companies will adopt such a concurrent focus on both the monitoring and the drug as a standard practice of drug development.

“MediaPharma has decided to join forces with Aegirbio by using its veritope technology coupled with our portfolio, including monoclonal antibodies, bispecifics and Antibody-Drug Conjugates (ADC)s, during the development phase. We believe that the addition of Therapeutic Drug Monitoring will enhance the treatment accuracy for patients,” says Stefano Iacobelli, CEO of MediaPharma Srl .

“It is exciting to be given the opportunity to utilize our Veritope technology together with a drug developing company. We believe ensuring at an early stage that therapies are individualized to be the future of drug development. Furthermore, it is our conviction that this will accelerate and secure the clinical trials. We take the fact that a successful team such as MediaPharma has chosen to cooperate with us as a further confirmation of our technology’s prowess,” says Martin Linde, CEO of Aegirbio AB.

About Aegirbio

Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.

The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.

The Company’s tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020, Aegirbio initiated sales in the U.S. of the MoNATor test for the drug Tysabri, which is used for treatment of the neurological disorder Multiple Sclerosis (MS). Aegirbio’s goal is to launch a total of four tests before 2023. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.

For more information, please visit Aegirbio’s website, www.aegirbio.com

Certified adviser for the company is Eminova Fondkommission AB  | +468-684 211 00 | info@eminova.se

About MediaPharma Srl

MediaPharma Srl, located in Rome and Chieti, Italy, is a drug discovery and development biotech company active in immuno-oncology and focusing on research and development of monoclonal antibodies, Antibody-Drug Conjugates (ADC)s and therapeutic proteins for treatment of cancer and other severe diseases with high medical need. Inherently innovative,

MediaPharma focuses specially on those cancers which have become resistant to previous drug regimens. At MediaPharma, world-class researchers, biologists, medical oncologists and entrepreneurs share the same values and have been working together for years to optimize patient’s treatment.

MediaPharma Srl
Via Colonnetta, 50/A
66000 Chieti
Italy

Pr. Stefano Iacobelli, CEO

Phone: +39 0871 563 273
Fax: +39 0871 563273

www.mediapharma.it